Banzel (Rufinamide) was developed in 2004 by Novartis Pharma. It is being manufactured by Eisai in Europe. It is indicated for the treatment of epileptic seizures which are associated with Lennox-Gastaut syndrome (LGS) (L~G症候群,雷葛氏症候群) in children and adults.